Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

BACKGROUND: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detai...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Farlow, Martin, Veloso, Felix, Moline, Margaret, Yardley, Jane, Brand-Schieber, Elimor, Bibbiani, Francesco, Zou, Heng, Hsu, Timothy, Satlin, Andrew
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2011
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126705/
https://ncbi.nlm.nih.gov/pubmed/21612646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-11-57
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi